DrugPatentWatch Database Preview

Details for Patent: 9,254,328

« Back to Dashboard

Which drugs does patent 9,254,328 protect, and when does it expire?

Patent 9,254,328 protects TYGACIL and is included in one NDA.

This patent has thirty patent family members in twenty-four countries.

Summary for Patent: 9,254,328

Title:	Tigecycline compositions and methods of preparation
Abstract:	The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
Inventor(s):	Fawzi; Mahdi B. (Morristown, NJ), Zhu; Tianmin (Monroe, NY), Shah; Syed M. (Delray Beach, FL)
Assignee:	Wyeth LLC (New York, NY)
Application Number:	14/604,924
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,254,328
Patent Claim Types: see list of patent claims	Composition; Formulation; Process;

Drugs Protected by US Patent 9,254,328

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821-001	Jun 15, 2005	AP	RX	Yes	Yes			Y

International Family Members for US Patent 9,254,328

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	053827
Argentina	109500
Australia	2006223226
Brazil	PI0608464
Canada	2602089